Mesa Laboratories, Inc. (MLAB) Financial Statements
Mesa Laboratories, Inc. (MLAB) reported trailing twelve-month revenue of $249.7M (up 3.0% year on year) and net income of $4.8M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $52.9M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MLABMesa Laboratories, Inc.Follow MLAB — free
—
Price chart with a free account
- Market cap
- 720.0M
- P/E TTM
- —
- Dividend yield
- 0.5%
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2012 Mar 12 | FY2013 Mar 13 | FY2014 Mar 14 | FY2015 Mar 15 | FY2016 Mar 16 | FY2017 Mar 17 | FY2018 Mar 18 | FY2019 Mar 19 | FY2020 Mar 20 | FY2021 Mar 21 | FY2022 Mar 22 | FY2023 Mar 23 | FY2024 Mar 24 | FY2025 Mar 25 | FY2026 Mar 26 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 39.6 | 46.4 | 52.7 | 71.3 | 84.7 | 93.7 | 96.2 | 103.1 | 117.7 | 133.9 | 184.3 | 219.1 | 216.2 | 241.0 | 249.1 | 249.7 | |
| Gross profit | 23.5 | 28.9 | 31.7 | 43.4 | 51.4 | 53.2 | 54.6 | 60.9 | 65.4 | 87.0 | 109.1 | 133.7 | 133.3 | 150.9 | 158.3 | 160.3 | |
| Research & development | 1.4 | 2.0 | 2.3 | 3.3 | 4.0 | 4.2 | 3.5 | 3.5 | 6.4 | 10.4 | 15.8 | 20.5 | 19.3 | 19.5 | 20.3 | 20.0 | |
| Operating income | 12.5 | 13.1 | 11.8 | 15.9 | 16.3 | 16.3 | 2.2 | 9.8 | 7.9 | 12.4 | 4.7 | 3.3 | -272.1 | 16.3 | 18.5 | 22.5 | |
| Pre-tax income | 12.3 | 13.0 | 13.1 | 15.3 | 15.6 | 14.3 | 0.3 | 8.6 | 3.9 | 2.3 | 3.6 | -0.4 | -275.6 | 6.0 | 12.0 | 9.4 | |
| Income tax | 4.4 | 4.5 | 4.1 | 5.8 | 4.4 | 3.1 | 3.3 | 1.1 | 2.1 | -1.0 | 1.7 | -1.3 | -21.4 | 7.9 | 5.3 | 4.6 | |
| Net income | 7.9 | 8.5 | 9.0 | 9.6 | 11.2 | 11.2 | -3.0 | 7.5 | 1.8 | 3.3 | 1.9 | 0.9 | -254.2 | -2.0 | 6.7 | 4.8 | |
| Diluted EPS ($) | 2.29 | 2.35 | 2.49 | 2.63 | 2.97 | 2.91 | -0.79 | 1.86 | 0.41 | 0.64 | 0.35 | 0.17 | -47.20 | -0.36 | 1.21 | 0.85 | |
| Diluted shares (mn) | 3.5 | 3.6 | 3.6 | 3.6 | 3.8 | 3.8 | 3.8 | 4.0 | 4.4 | 5.1 | 5.3 | 5.4 | 5.4 | 5.4 | 5.6 | — |
USD millions · SEC XBRL
Mesa Laboratories, Inc. — questions
- What is Mesa Laboratories, Inc.'s revenue?
- $249.7M over the twelve months to 2026-06-30, up 3.0% year on year, from its 10-Q and 10-K filings.
- What is Mesa Laboratories, Inc.'s net income?
- $4.8M over the twelve months to 2026-06-30.
- What is Mesa Laboratories, Inc.'s free cash flow?
- $52.9M over the twelve months to 2026-06-30.
- What are Mesa Laboratories, Inc.'s diluted earnings per share?
- $0.85 over the twelve months to 2026-06-30.
Every figure on this page comes from Mesa Laboratories, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.